Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
The present invention provides a novel compound represented by Chemical Formula 1 or a salt thereof and a pharmaceutical composition for treating lung cancer containing same. A pyrimidine derivative compound represented by Chemical Formula 1 effectively inhibits the growth of cancer cells with an ALK mutation and an EGFR mutation, thereby being effectively usable in the treatment of lung cancer.
1. A compound of Chemical Formula 1 below or a salt thereof:
X is oxygen,
R 1 is an alkyl group of C1 to C4, or a cycloalkyl group of C3 to C6,
R 2 is H or an alkyl group of C1 to C4,
R 3 is hydrogen or a halogen group,
R 4 is hydrogen, a halogen group, or an alkyl group of C1 to C4, R 5 is hydrogen or an alkyl group of C1 to C4,
R 6 is hydrogen or an alkyl group of C1 to C4,
R 7 is a pyrazolyl group unsubstituted or substituted with a C1 to C4 alkyl group, an imidazolyl group unsubstituted or substituted with a C1 to C4 alkyl group, or a triazolyl group unsubstituted or substituted with a C1 to C4 alkyl group, and
R 8 is a morpholinyl group unsubstituted or substituted with a C1 to C4 alkyl group, a thiomorpholinyl group unsubstituted or substituted with a C1 to C4 alkyl group, piperazinyl group unsubstituted or substituted with a C1 to C4 alkyl group, a diazaspiro group of C5 to C10 unsubstituted or substituted with a C1 to C4 alkyl group, an oxoazaspiro group of C5 to C10 unsubstituted or substituted with a C1 to C4 alkyl group, a thioazaspiro group of C5 to C10 unsubstituted or substituted with a C1 to C4 alkyl group, or a N 1 ,N 1 ,N 2 -tri (C1 to C4 alkyl)ethylene diamine group,
wherein X forms a double bond with S, and S forms a single bond with N.
2. The compound of Chemical Formula 1 or the salt thereof of claim 1 , wherein
the R 7 is selected from the following groups, and
the R 8 is selected from the following groups:
3. The compound of Chemical Formula 1 or the salt thereof of claim 1 , wherein
X is oxygen,
R 1 is an alkyl group of C1 to C4,
R 2 is H or an alkyl group of C1 to C4,
R 3 is hydrogen or a halogen group,
R 4 is hydrogen or a halogen group,
R 5 is hydrogen or an alkyl group of C1 to C4,
R 6 is an alkyl group of C1 to C4,
R 7 is selected from the following groups, and
R 8 is selected from the following groups:
4. The compound of Chemical Formula 1 or the salt thereof of claim 1 , wherein
the compound of Chemical Formula 1 is selected from the following compounds:
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morpholinophenyl)amino)pyrimidine-4-yl)amino)phenyl)-N-methylmethanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morpholinophenyl)amino)pyrimidine-4-yl)amino)phenyl)methanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-thiomorpholinophenyl)amino)pyrimidine-4-yl)amino)phenyl)-N-methoxymethanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazine-1-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)-N-methoxymethanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)-N-methylmethanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(6-methyl-2,6-diazaspiro[3.3]heptane-2-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)-N-methylmethanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-thiomorpholinophenyl)amino)pyrimidine-4-yl)amino)phenyl)methanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazine-1-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)methanesulfonamide,
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)methanesulfonamide, and
N-(2-((5-chloro-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(6-methyl-2,6-diazaspiro[3.3]heptane-2-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)methanesulfonamide.
5. The compound of Chemical Formula 1 or the salt thereof of claim 1 , wherein
the salt is a salt of an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, benzoic acid, hydroxybenzoic acid, phenyl acetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzene sulfonic acid, and toluene sulfonic acid.
6. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, as an active ingredient, and a pharmaceutically acceptable carrier.
7. A method for treating lung cancer in a subject in need thereof, comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to the subject.
8. The method of claim 7 , wherein
the lung cancer is anaplastic lymphoma kinase (ALK) mutation and epidermal growth factor receptor (EGFR) expression lung cancer.